Positive News SentimentPositive NewsNASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $0.98 +0.03 (+3.14%) Closing price 04:00 PM EasternExtended Trading$0.98 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytosorbents Stock (NASDAQ:CTSO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytosorbents alerts:Sign Up Key Stats Today's Range$0.94▼$0.9950-Day Range$0.84▼$1.2952-Week Range$0.71▼$1.61Volume72,560 shsAverage Volume188,163 shsMarket Capitalization$61.50 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingModerate Buy Company Overview Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Read More Cytosorbents Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 43% of companies evaluated by MarketBeat, and ranked 716th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.37% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Cytosorbents has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.37% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Cytosorbents has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News SentimentN/A News SentimentCytosorbents has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cytosorbents this week, compared to 2 articles on an average week.Search Interest3 people have searched for CTSO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTSO Stock News HeadlinesCytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATRAugust 20, 2025 | finanznachrichten.deCytoSorbents provides update of its appeal with FDA regarding DrugSorb-ATRAugust 20, 2025 | msn.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. September 3 at 2:00 AM | Crypto 101 Media (Ad)CTSO: CytoSorbents Announces the De Novo denial on DrugSorb-ATR was upheld by the FDA. However, a Path to Approval Was Also Provided by the Agency.August 20, 2025 | finance.yahoo.comCytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATRAugust 20, 2025 | prnewswire.comCTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00.August 14, 2025 | finance.yahoo.comCytosorbents Corp Q2 2025 Earnings Call HighlightsAugust 13, 2025 | msn.comCytosorbents Corporation (CTSO) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO shares have increased by 7.7% and is now trading at $0.98. How were Cytosorbents' earnings last quarter? Cytosorbents Corporation (NASDAQ:CTSO) posted its quarterly earnings data on Thursday, August, 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The medical research company had revenue of $9.62 million for the quarter, compared to analyst estimates of $9.79 million. Cytosorbents had a negative net margin of 25.58% and a negative trailing twelve-month return on equity of 111.97%. Read the conference call transcript. Who are Cytosorbents' major shareholders? Cytosorbents' top institutional shareholders include Avenir Corp (8.06%) and Geode Capital Management LLC (0.96%). Insiders that own company stock include Phillip P Chan, Alan D Sobel, Michael G Bator and Kathleen P Bloch. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU). Company Calendar Last Earnings8/07/2025Today9/03/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year Founded2002Price Target and Rating Average Price Target for Cytosorbents$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+478.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.72 million Net Margins-25.58% Pretax Margin-31.34% Return on Equity-111.97% Return on Assets-29.00% Debt Debt-to-Equity Ratio1.24 Current Ratio2.34 Quick Ratio1.96 Sales & Book Value Annual Sales$35.60 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book5.28Miscellaneous Outstanding Shares62,760,000Free Float58,620,000Market Cap$59.63 million OptionableOptionable Beta1.28 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CTSO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.